Background: Oxaliplatin-based electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC-OX) is an emerging treatment option for patients with unresectable colorectal peritoneal metastases (CPM). CRC-PIPAC was the first trial that prospectively investigated repetitive ePIPAC-OX monotherapy without concomitant systemic therapy for patients with unresectable colorectal peritoneal metastases. The present study assessed the total costs of repetitive ePIPAC-OX monotherapy.

Background: A resection with clear resection margins (R0 resection) is the single most important prognostic factor for overall and local recurrence free survival in patients with locally recurrent rectal cancer (LRRC). However, despite the use of neoadjuvant chemo(re)irradiation, an R0 resection is achieved in only ±60% of patients. Induction chemotherapy in addition to neoadjuvant chemoradiotherapy is increasingly being used, as this combination may increase the R0 resection rate. Still, evidence for any beneficial effect of induction chemotherapy is lacking.